Leflunomide对实验性IgA肾病大鼠肾脏病理及MCP-1表达的影响

Effects of leflunomide on renal pathology and expression of MCP-1 in renal tissue in rat experimental IgA nephropathy model

目的观察leflunomide对实验性IgA肾病(IgAnephropathyIgAN)大鼠肾脏病理及肾组织单核细胞趋化因子(monocytechemoattractivepeptide1,MCP-1)表达的影响,了解其作用机制。方法建立IgAN大鼠模型,随机分成leflunomide组,强的松组,模型对照组,并同时设立正常对照组。行免疫荧光、光镜检查,并用免疫组化和RT-PCR方法分别检测肾组织MCP-1蛋白和基因水平的表达。结果与模型对照组相比,leflunomide组免疫复合物在肾脏的沉积明显减少,系膜区基质增生程度显著减轻(P<0.01);Leflunomide在基因和蛋白水平均能够有效抑制MCP-1在肾组织的表达(P<0.05)。结论Leflunomide能够减少免疫复合物在肾脏的沉积,减轻系膜区基质增生,并且下调MCP-1在肾脏的表达,减少局部炎症反应,减轻肾脏损害,保护肾脏。

[Objective] To observe the effects of leflunomide on renal pathology and expression of monocyte ehemoattraetive peptidel （MCP-1） in rat experimental IgA nephropathy model renal tissue at level of gene mad protein, which can help to understand mechanism of action. [Methods] Firstly, we constructed IgA nephropathy model, then divided models into leflunomide group,prednisone group, model control group, as well as normal control group . We performed immunofluorescence, light microscope and expression of MCP-1 at the level of gene and protein in renal tissue by immunohistochemistry and RT-PCR methods. [Results] Compared with model control, leflunomidc lessened the deposit of immunocomplex in renal tissue,diminished the hyperplasia of mesangial matrix （P 〈0.01）; leflunomide could inhibit the expression of MCP-1 at the level of gene and protein in renal tissue （P 〈0.05）. [Conclusion] leflunomide can decrease the deposition of immunocomplex, relieve the hyperplasia of mesangial matrix and downregulate the expression of MCP-1 in kidney, diminish local inflammatory reaetion, relieve renal loss and protect renal function.